Copyright
©The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Oncol. Oct 10, 2017; 8(5): 405-411
Published online Oct 10, 2017. doi: 10.5306/wjco.v8.i5.405
Published online Oct 10, 2017. doi: 10.5306/wjco.v8.i5.405
Factors influencing response to ingenol mebutate therapy for actinic keratosis of face and scalp
Nevena Skroza, Ilaria Proietti, Nicoletta Bernardini, Veronica Balduzzi, Alessandra Mambrin, Anna Marchesiello, Ersilia Tolino, Sara Zuber, Concetta Potenza, Dermatology Unit “Daniele Innocenzi”, Department of Medical and Surgical Sciences and Biotechnologies, Sapienza University of Rome, 04019 Terracina, Italy
Giuseppe La Torre, Department of Public Health and Infectious Diseases, Sapienza University of Rome, 04019 Terracina, Italy
Author contributions: Skroza N, Proietti I, Bernardini N and Potenza C designed the research; Balduzzi V, Mambrin A, Marchesiello A, Tolino E and Zuber S performed the research; La Torre G analyzed the data.
Institutional review board statement: The study was reviewed and approved by the Ospedale A. Fiorini Institutional Review Board.
Informed consent statement: All study participants, or their legal guardian, provided informed written consent prior to study enrollment.
Conflict-of-interest statement: The author reports no conflict of interest.
Data sharing statement: No additional data are available.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Nevena Skroza, MD, Dermatology Unit “Daniele Innocenzi”, Department of Medical and Surgical Sciences and Biotechnologies, Sapienza University of Rome, Via Firenze snc Polo Pontino, 04019 Terracina, Italy. nevena.skroza@uniroma1.it
Telephone: +39-773-708811 Fax: +39-773-708399
Received: October 20, 2016
Peer-review started: October 23, 2016
First decision: December 20, 2016
Revised: July 6, 2017
Accepted: September 1, 2017
Article in press: September 1, 2017
Published online: October 10, 2017
Peer-review started: October 23, 2016
First decision: December 20, 2016
Revised: July 6, 2017
Accepted: September 1, 2017
Article in press: September 1, 2017
Published online: October 10, 2017
Core Tip
Core tip: Ingenol mebutate 0.015% gel is an effective treatment for non-hypertrophic non-hyperkeratotic actinic keratosis of face and scalp. Facial lesions are more prone to achieve a complete response to this therapy than those located on the scalp. Facial localization and the highest levels of local skin reaction, in particular the amount of crusting, are predictive for complete response to ingenol mebutate 0.015% gel therapy in a real clinical setting.